MetaStat

MetaStat EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of MetaStat (MTST) as of Oct 6, 2026 is -0.20. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -0.06 — a change of 216.36% (lower).

EV/EBITDA

-0.20

YoY

216.36%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of MetaStat is 2026 -0.20 . EV/EBITDA (Enterprise Value to EBITDA) of MetaStat was 2025 -0.06 . It decreases by 216.36% lower compared to the previous year.

The MetaStat EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2014
-0.46 USD
Jan 1, 2015
-0.00 USD
Jan 1, 2016
-0.25 USD
Jan 1, 2017
-0.06 USD
Jan 1, 2018
-0.20 USD
The MetaStat EV/EBITDA history
YEAREV/EBITDAYoY
-0.20+216.36%
-0.06-74.45%
-0.25+7,522.07%
-0.00-99.30%
-0.46—
Access this data via the Eulerpool API

MetaStat Stock analysis

What does MetaStat do? MetaStat Inc. is a biopharmaceutical company focused on the development of therapeutics for cancer. It was founded in Massachusetts in 2000 and has been listed on NASDAQ since 2013. The company's main focus is on blocking the protein Meta-1, which is associated with the formation of metastases, in order to stop the spread of cancer. MetaStat's business model is based on marketing medications and diagnostics. They work closely with researchers and clinicians to develop new products and conduct clinical trials. The company operates in two divisions: therapeutics and diagnostics. The therapeutics division focuses on developing medications targeting the Meta-1 protein, while the diagnostics division develops tests to detect Meta-1 protein in patients' blood to identify metastases early on. MetaStat's main product is the MetaSite Breast Test, a diagnostic test for breast cancer that uses proprietary technologies to detect the presence of Meta-1 in tumor tissue. The company also has several therapeutics in the pipeline, with MSC-1, a small molecule that blocks the function of Meta-1 and inhibits the formation of metastases, being the leading product. MetaStat has established partnerships with several research institutions and companies to advance its research and development. In summary, MetaStat is a biopharmaceutical company specializing in the development of therapeutics and diagnostics for cancer. They have developed innovative technology to detect the presence of Meta-1 in tumor tissue and inhibit the formation of metastases. Their main product is the MetaSite Breast Test, which determines the risk of metastases in breast cancer patients. The company has established partnerships with research institutions and companies to advance its research and development and further develop its pipeline of therapeutics. MetaStat is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MetaStat stock

EV/EBITDA (Enterprise Value to EBITDA) of MetaStat is -0.20 in 2026.

EV/EBITDA (Enterprise Value to EBITDA) of MetaStat changed from -0.06 to -0.20, representing a 216.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) MetaStat since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s MetaStat with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — MetaStat

All Key Metrics — MetaStat